Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.69 |
| ▸ | LMNA | P02545 | 9/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.69 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.69 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063539 | 0.87 | GLO1 (0.54) | MAPTLMNAKMT2AMEN1PLIN1 | |
| SCHEMBL17619350 | 0.86 | GLO1 (0.53) | MAPTLMNAKMT2AMEN1PLIN1 | |
| SCHEMBL25367057 | 0.84 | ALDH1A1 (0.67) | MAPTLMNAKMT2AMEN1PLIN1 | |
| SCHEMBL6341533 | 0.82 | MAPT (0.48) | MAPTLMNAKMT2AMEN1PLIN1 | |
| SCHEMBL9494896 | 0.82 | KMT2A (1.00) | MAPTLMNAKMT2AMEN1PLIN1 | |
| SCHEMBL1373654 | 0.80 | MAPT (0.71) | MAPTLMNAKMT2AMEN1PLIN1 | |
| SCHEMBL10318091 | 0.78 | ALDH1A1 (0.72) | MAPTLMNAKMT2AMEN1PLIN1 | |
| SCHEMBL9052309 | 0.78 | MEN1 (0.70) | MAPTLMNAKMT2AMEN1PLIN1 | |
| SCHEMBL18304687 | 0.77 | HPGD (0.49) | MAPTLMNAKMT2AMEN1PLIN1 | |
| SCHEMBL13690244 | 0.76 | LMNA (0.42) | MAPTLMNAKMT2AMEN1PLIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286428-B2 | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-29 | — | — | US | disclosed |
| CN-114423757-B | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-3999508-B1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3999508-B1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20220259205-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-08-18 | — | — | US | disclosed |
| EP-3999508-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-05-25 | — | — | EP | disclosed |
| CN-114423757-A | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2021011724-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2021011724-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-01-21 | — | — | WO | disclosed |
| US-7618980-B2 | Pyrrolo(oxo)quinolines as 5HT ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1773833-A4 | PYRROLO(OXO)QUINOLINES AS 5HT LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-1773833-A2 | PYRROLO(OXO)QUINOLINES AS 5HT LIGANDS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006019940-A2 | PYRROLO(OXO)QUINOLINES AS 5HT LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060014778-A1 | (+-)-cis 6-Methoxy-8-phenyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,4-c]quinoline; serotonin receptor modulators; obesity, diabetes, atherosclerosis, dyslipidemia; central nervous system diseases like anxiety, depression, OCD, panic disorder, psychosis, schizophrenia, sleep and sexual disorders, | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014778-A1 | (+-)-cis 6-Methoxy-8-phenyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,4-c]quinoline; serotonin receptor modulators; obesity, diabetes, atherosclerosis, dyslipidemia; central nervous system diseases like anxiety, depression, OCD, panic disorder, psychosis, schizophrenia, sleep and sexual disorders, | HTR3B, HTR2C, HTR2B | MAPT 2359/4885LMNA 3641/4885KMT2A 2922/4885 |
| US-20220259205-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | IRAK4, IRAK1, IRAK3 | MAPT 4345/4885LMNA 1227/4885KMT2A 327/4885 |
| US-12286428-B2 | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | IRAK4, IRAK1, IRAK3 | MAPT 4345/4885LMNA 1227/4885KMT2A 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.